Drugs / rBV A/B-40
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 2 | NCT00764634 Comparator | Sep 2008 → Mar 2010 | botulism | DynPort Vaccine Company LLC, A GDIT Company | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | rBV A/B-40 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00764634 ↗ |
| Modality | Vaccine | “rBV A/B-40 vaccine” NCT00764634 ↗ |
| Route | Intramuscular | “0.5 mL dose of rBV A/B-40 vaccine given by intramuscular injection” NCT00764634 ↗ |